Latest revenue
$39.5M
as of 2026-03-31
Latest net income
$-3.8M
as of 2026-03-31
Net margin
-9.6%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $29.9M
- Enterprise value
- $29.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.23
- 52-wk low
- $0.06
- Beta
- —
- Shares out
- 399.3M
5-year trend
What this company does
Item 1. Business Company Overview We are a multi-state cannabis operator (“MSO”) in the United States, headquartered in Norwood, Massachusetts, dedicated to improving lives every day through our high-quality products, our actions, and our values. We develop, own, and manage seed to sale state-licensed, state-of-the-art, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. We have created and continue to develop our own brands of premium cannabis flower, concentrates, edibles, and other precision-dosed products utilizing our proprietary strains and formulations. We also license our proprietary brands, in select domestic markets,…
AI summary unavailable — showing raw filing excerpt
Generated from MRMD's filing dated 2026-03-12
Key risks
Item 1A. Risk Factors Our business faces significant risks and uncertainties. Certain important factors may have a material adverse effect on our business prospects, financial condition and results of operations, and they should be carefully considered. Accordingly, in evaluating our business, and a potential investment in our shares, we encourage you to consider the following discussion of risk factors in its entirety in addition to other information contained in or incorporated by reference into this Annual Report on Form 10-K and our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business,…
AI summary unavailable — showing raw filing excerpt
Generated from MRMD's filing dated 2026-03-12
Profitability
Gross margin
36.2%
9.0%Operating margin
-1.8%
195.7%Net margin
-9.1%
14.8%Return on assets
-7.2%
18.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $39.5M | +4.2% | $-3.8M | +30.6% | -9.6% |
Q4 2025 2025-12-31 | $41.5M | +6.5% | $-4.8M | +43.4% | -11.6% |
Q3 2025 2025-09-30 | $40.8M | +0.4% | $-2.9M | -193.0% | -7.2% |
Q2 2025 2025-06-30 | $39.6M | -2.0% | $-1.3M | +23.1% | -3.2% |
Q1 2025 2025-03-31 | $37.9M | -0.1% | $-5.5M | -320.0% | -14.4% |
Q4 2024 2024-12-31 | $39.0M | — | $-8.5M | — | -21.8% |
Q3 2024 2024-09-30 | $40.6M | +4.6% | $-1.0M | +76.4% | -2.5% |
Q2 2024 2024-06-30 | $40.4M | +10.7% | $-1.7M | -72.3% | -4.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Medicinal Chemicals & Botanical Products · SIC 2833
Your notes
Keep private notes on MRMD — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$7.9K
Insider selling
$0
Net activity
+$7.9K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns MRMD
Institutional value
$44.5K
Total shares held
645.2K
Distinct holders
2
-2 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Canton Hathaway, LLC | 645.1K | $44.4K | +0 (+0.0%) | No change |
| 2 | Game Plan Financial Advisors, LLC | 100 | $7 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once MRMD's latest filing finishes processing.